When eczema won't budge, think harder — not just harder treatments

The American Academy of Dermatology (AAD) has published its first-ever guidelines for adults whose atopic dermatitis (AD) doesn't respond to treatment — and the core message is surprisingly simple: don't just escalate therapy. Instead, clinicians should pause and ask why the treatment isn't working.

The guidelines, published in the Journal of the American Academy of Dermatology, emphasize that treatment failure could signal a misdiagnosis, an overlooked comorbidity, or a barrier to adherence — not necessarily true refractory AD. Conditions like contact dermatitis, psoriasis, cutaneous T-cell lymphoma, food allergies, and allergic rhinitis can all mimic or worsen AD, complicating the clinical picture.

A targeted diagnostic workup — including patch testing, skin biopsy, bacterial culture, and skin scrapings — is recommended based on each patient's specific presentation, history, and treatment response. Notably, there is no single confirmatory test for AD.

Key Takeaways:

• Reassess the diagnosis before assuming true refractory AD
• Rule out mimics: contact dermatitis, psoriasis, urticaria, and cutaneous T-cell lymphoma
• Evaluate barriers: access, adherence, tolerability, and treatment complexity
• Let clinical presentation guide targeted testing — avoid both over- and under-testing
• Whole-person care matters: uncontrolled comorbidities can drive treatment failure

Why it matters: With approximately 2% of adults worldwide affected by AD — and adult-onset cases on the rise — these guidelines give clinicians a practical framework to avoid unnecessary therapy escalation and improve outcomes through smarter, more individualized diagnosis.